Newborn screening for inborn errors of metabolism

Bridget Wilcken, Piero Rinaldo, Dietrich Matern

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Scopus citations

Abstract

Newborn screening was first applied to the detection of phenylketonuria (PKU) by a bacterial inhibition assay pioneered in 1961 by Guthrie, who was also responsible for the introduction of the use of a dried blood sample [1]. This was followed by further bacterial inhibition assays to detect other aminoacidopathies (maple syrup urine disease, homocystinuria, urea cycle disorders, etc.), but only screening for PKU was widely adopted. In 1975 Dussault described screening for congenital hypothyroidism (CH) [2], and since then other disorders covered in some screening programmes have included congenital adrenal hyperplasia, the galactosaemias, cystic fibrosis, biotinidase deficiency, glucose-6-phosphate dehydrogenase deficiency and many others.

Original languageEnglish (US)
Title of host publicationInborn Metabolic Diseases: Diagnosis and Treatment
PublisherSpringer Berlin Heidelberg
Pages75-86
Number of pages12
ISBN (Print)9783642157202, 9783642157196
DOIs
StatePublished - Jan 1 2012

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wilcken, B., Rinaldo, P., & Matern, D. (2012). Newborn screening for inborn errors of metabolism. In Inborn Metabolic Diseases: Diagnosis and Treatment (pp. 75-86). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-15720-2_3